Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Orbassano – page 11

215 clinical trials in Orbassano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Orbassano at a glance
215
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

215 trials in Orbassano

Open in trial search

Lung disorder

Not recruiting

Study on the Effectiveness of Osimertinib for Patients with EGFR Mutant Non-Small Cell Lung Cancer Based on TP53 Mutation Status

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Effectiveness of Autologous Stem Cell Transplantation with Cytarabine in Patients with Aggressive Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Alemtuzumab
  • Sponsor:Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S

Cushing's syndrome

Not recruiting

Study on the Long-Term Safety of Relacorilant for Patients with Cushing Syndrome

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Corcept Therapeutics Inc.

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Osimertinib and Datopotamab Deruxtecan for Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Anaplastic lymphoma kinase gene mutation

Not recruiting

Study Comparing Alectinib and Crizotinib for Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Acute myeloid leukaemia

Not recruiting

Study on the Safety and Effectiveness of Ivosidenib or Enasidenib with Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia with IDH1 or IDH2 Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Celgene Corp.

Prostate cancer

Not recruiting

Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Medivation Inc.

Non-small cell lung cancer+1

Not recruiting

Study of Amivantamab and Cetrelimab for Patients with Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Thalassaemia

Not recruiting

Study on the Effectiveness and Safety of Mitapivat for Patients with Non-Transfusion-Dependent Alpha or Beta Thalassemia

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Hormone-refractory prostate cancer+1

Not recruiting

Study on Radium-223, Docetaxel, and Prednisone for Patients with Bone-Only Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Anxiety disorder

Not recruiting

Study on Troriluzole for Patients with Obsessive Compulsive Disorder Not Responding to Current Treatment

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Troriluzole
  • Sponsor:Biohaven Pharmaceuticals Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Orbassano

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer and mesothelioma treatments, including studies of novel therapeutic combinations and targeted therapies.

  • Non-Small Cell Lung Cancer (NSCLC) Studies
  • Pleural Mesothelioma Treatments
  • Renal Cell Carcinoma Research

Multiple trials evaluating immunotherapy approaches and targeted molecular treatments for advanced stages of cancer.

02 Hematological Disorders

Research initiatives investigating treatments for blood disorders and related conditions, with particular focus on innovative therapies.

  • Sickle Cell Disease Management
  • Acute Myeloid Leukemia Treatments
  • Lymphoblastic Leukemia Studies

Studies examining new therapeutic approaches for blood disorders and their complications.

03 Cardiovascular Research

Clinical investigations focusing on heart failure prevention and innovative cardiovascular treatments.

  • Heart Failure Prevention Studies
  • Cardiovascular Risk Management
  • Novel Drug Combinations

Trials evaluating new therapeutic approaches for reducing cardiovascular events and improving patient outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.